Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 resTORbioIVERIC bioKalVista PharmaceuticalsClovis OncologyFoghorn Therapeutics
SymbolNASDAQ:TORCNASDAQ:ISEENASDAQ:KALVNASDAQ:CLVSNASDAQ:FHTX
Price Information
Current Price$12.24$5.83$23.01$5.84$10.56
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.01.51.81.41.5
Analysis Score1.03.34.53.03.5
Community Score2.52.23.02.53.6
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.70.80.0
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$4.00$13.00$50.17$9.50$24.67
% Upside from Price Target-67.32% downside122.98% upside118.02% upside62.67% upside133.59% upside
Trade Information
Market Cap$446.20 million$536.51 million$594.33 million$625.09 million$423.40 million
Beta2.431.682.132.1N/A
Average Volume1,153,737610,654953,82412,486,63898,035
Sales & Book Value
Annual RevenueN/AN/A$12.69 million$143.01 millionN/A
Price / SalesN/AN/A44.084.27N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.24 per share$2.82 per share$4.69 per share($3.17) per shareN/A
Price / BookN/AN/A4.91-1.84N/A
Profitability
Net Income$-82,740,000.00$-58,860,000.00$-29,120,000.00$-400,420,000.00N/A
EPS($2.41)($1.39)($1.64)($7.60)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-229.45%-230.34%N/A
Return on Equity (ROE)-78.12%-45.42%-47.45%N/AN/A
Return on Assets (ROA)-71.63%-41.94%-41.84%-57.56%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio20.69%11.76%7.56%2.33%N/A
Quick Ratio20.69%11.76%7.56%2.14%N/A
Ownership Information
Institutional Ownership Percentage46.19%84.80%90.19%57.83%N/A
Insider Ownership Percentage11.80%4.30%18.00%6.60%N/A
Miscellaneous
EmployeesN/A5756N/A85
Shares Outstanding36.45 million90.17 million24.31 million104.53 million36.82 million
Next Earnings DateN/A5/5/2021 (Estimated)7/7/2021 (Estimated)5/4/2021 (Estimated)N/A
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Foghorn Therapeutics Inc (FHTX)Foghorn Therapeutics Inc (FHTX)
investing.com - April 14 at 7:16 AM
Foghorn Therapeutics Inc.s (NASDAQ:FHTX) Lock-Up Period To End  on April 21stFoghorn Therapeutics Inc.'s (NASDAQ:FHTX) Lock-Up Period To End on April 21st
americanbankingnews.com - April 14 at 1:32 AM
Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?
finance.yahoo.com - April 1 at 1:59 PM
Morgan Stanley Trims Foghorn Therapeutics (NASDAQ:FHTX) Target Price to $23.00Morgan Stanley Trims Foghorn Therapeutics (NASDAQ:FHTX) Target Price to $23.00
americanbankingnews.com - March 29 at 10:02 AM
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
finance.yahoo.com - March 24 at 12:29 PM
FHTX Stock Price Increased 36.61%: Why It HappenedFHTX Stock Price Increased 36.61%: Why It Happened
pulse2.com - March 21 at 1:54 PM
Foghorn Therapeutics Provides Corporate UpdateFoghorn Therapeutics Provides Corporate Update
finance.yahoo.com - March 18 at 9:51 AM
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
apnews.com - March 12 at 9:40 PM
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
finance.yahoo.com - March 11 at 8:31 PM
UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021
finance.yahoo.com - March 11 at 8:31 PM
Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare ConferenceFoghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference
finance.yahoo.com - February 22 at 1:00 PM
Foghorn Therapeutics Inc. (FHTX)Foghorn Therapeutics Inc. (FHTX)
finance.yahoo.com - February 2 at 12:35 AM
What Is The Ownership Structure Like For Foghorn Therapeutics Inc. (NASDAQ:FHTX)?What Is The Ownership Structure Like For Foghorn Therapeutics Inc. (NASDAQ:FHTX)?
finance.yahoo.com - January 23 at 12:50 PM
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateFoghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - December 4 at 8:10 AM
Foghorn Therapeutics Inc. Common Stock (FHTX)Foghorn Therapeutics Inc. Common Stock (FHTX)
nasdaq.com - November 23 at 5:33 PM
Foghorn Therapeutics Rings the Opening Bell in Celebration of its IPOFoghorn Therapeutics Rings the Opening Bell in Celebration of its IPO
nasdaq.com - October 29 at 4:44 PM
Foghorn Therapeutics Inc.Foghorn Therapeutics Inc.
reuters.com - October 29 at 4:44 PM
DateCompanyBrokerageAction
5/28/2020resTORbioFIG PartnersReiterated Rating
4/29/2020resTORbioEvercore ISIUpgrade
11/15/2019resTORbioSVB LeerinkDowngrade
11/15/2019resTORbioWedbushDowngrade
11/15/2019resTORbioGuggenheimDowngrade
11/15/2019resTORbioCantor FitzgeraldDowngrade
8/13/2020IVERIC bioCredit Suisse GroupInitiated Coverage
1/24/2020IVERIC bioCowenInitiated Coverage
9/18/2019IVERIC bioChardan CapitalReiterated Rating
2/25/2021KalVista PharmaceuticalsRoth CapitalBoost Price Target
2/10/2021KalVista PharmaceuticalsHC WainwrightBoost Price Target
2/9/2021KalVista PharmaceuticalsJefferies Financial GroupBoost Price Target
2/9/2021KalVista PharmaceuticalsStifel NicolausBoost Price Target
1/26/2021KalVista PharmaceuticalsNeedham & Company LLCBoost Price Target
11/5/2020Clovis OncologyPiper SandlerLower Price Target
11/1/2020Clovis OncologyJPMorgan Chase & Co.Reiterated Rating
4/20/2020Clovis OncologyRoyal Bank of CanadaReiterated Rating
4/19/2020Clovis OncologyBank of AmericaDowngrade
10/31/2019Clovis OncologyPiper Jaffray CompaniesLower Price Target
3/29/2021Foghorn TherapeuticsMorgan StanleyLower Price Target
11/17/2020Foghorn TherapeuticsThe Goldman Sachs GroupInitiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.